Skip to main content
. Author manuscript; available in PMC: 2019 Nov 26.
Published in final edited form as: Pharmacol Res. 2019 Feb 7;142:267–282. doi: 10.1016/j.phrs.2019.02.002

Fig. 3.

Fig. 3.

Brain permeant and impermeant inhibitors of FAAH prevent the development of paclitaxel-induced allodynia. Prophylactic dosing with the brain permeant FAAH inhibitor URB597 (1 mg/kg i.p. × 20 days) and the brain impermeant FAAH inhibitor URB937 (1 mg/kg i.p. × 20 days) suppresses the development of paclitaxel-induced (A) mechanical and (B) cold hypersensitivities with similar efficacy. By contrast, the orthosteric cannabinoid agonist WIN55,212–2 (3 mg/kg i.p. × 20 days) initially suppressed paclitaxel-induced mechanical and cold hypersensitivity although tolerance developed to the observed antinociceptive effects. Rimonabant (10 mg/kg i.p.) challenge increased the number of bouts of (C) paw tremors and (D) scratching behaviors. Drug treatment did not alter the expression of either behavior. Data are expressed as mean ± SEM (n = 5–6 per group) *p < 0.05 all groups vs. vehicle, Xp < 0.05 URB597, URB937 vs. vehicle two-way repeated measures ANOVA followed by Bonferroni post hoc. (C, D) *p < 0.05 vs. vehicle challenge, two-way repeated measures ANOVA, +p < 0.05 vs. all groups two-way ANOVA followed by Bonferroni post hoc test.